Stay updated on Bispecific Antibody MCLA-158 Clinical Trial

Sign up to get notified when there's something new on the Bispecific Antibody MCLA-158 Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Bispecific Antibody MCLA-158 Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    Change Detected
    Difference
    0.1%
    Check dated 2025-03-05T00:43:48.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    0.8%
    Check dated 2025-02-25T19:17:14.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Difference
    0.1%
    Check dated 2025-02-18T13:54:28.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    0.9%
    Check dated 2025-02-11T10:03:31.000Z thumbnail image
  7. Check
    44 days ago
    Change Detected
    Summary
    The study has closed enrollment for several cohorts, including single-agent MCLA-158 for head and neck squamous cell carcinoma and combination therapy with pembrolizumab, while exploring new cohorts for MCLA-158 in combination with FOLFIRI and FOLFOX in metastatic colorectal cancer patients.
    Difference
    28%
    Check dated 2025-02-04T05:38:00.000Z thumbnail image
  8. Check
    58 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.0 to 2.14.1.
    Difference
    0.0%
    Check dated 2025-01-21T00:31:17.000Z thumbnail image

Stay in the know with updates to Bispecific Antibody MCLA-158 Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Bispecific Antibody MCLA-158 Clinical Trial page.